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Abstract
Background: An array of experimental models have been developed in the small model organisms C. elegans, S.
cerevisiae and D. melanogaster for the study of various neurodegenerative diseases including Alzheimer’s disease,
Parkinson’s disease, and expanded polyglutamine diseases as exemplified by Huntington’s disease (HD) and related
ataxias. Genetic approaches to determine the nature of regulators of the disease phenotypes have ranged from small
scale to essentially whole genome screens. The published data covers distinct models in all three organisms and one
important question is the extent to which shared genetic factors can be uncovered that affect several or all disease
models. Surprisingly it has appeared that there may be relatively little overlap and that many of the regulators may be
organism or disease-specific. There is, however, a need for a fully integrated analysis of the available genetic data based
on careful comparison of orthologues across the species to determine the real extent of overlap.
Results: We carried out an integrated analysis using C. elegans as the baseline model organism since this is the
most widely studied in this context. Combination of data from 28 published studies using small to large scale
screens in all three small model organisms gave a total of 950 identifications of genetic regulators. Of these 624
were separate genes with orthologues in C. elegans. In addition, 34 of these genes, which all had human
orthologues, were found to overlap across studies. Of the common genetic regulators some such as chaperones,
ubiquitin-related enzymes (including the E3 ligase CHIP which directly links the two pathways) and histone
deacetylases were involved in expected pathways whereas others such as the peroxisomal acyl CoA-oxidase
suggest novel targets for neurodegenerative disease therapy
Conclusions: We identified a significant number of overlapping regulators of neurodegenerative disease models.
Since the diseases have, as an underlying feature, protein aggregation phenotypes it was not surprising that some
of the overlapping genes encode proteins involved in protein folding and protein degradation. Interestingly,
however, some of the overlapping genes encode proteins that have not previously featured in targeted studies of
neurodegeneration and this information will form a useful resource to be exploited in further studies of potential
drug-targets.
Background
Despite major advances, debilitating neurodegenerative
diseases including Alzheimer’s disease (AD), Parkinson’s
disease (PD), and polyglutamine (polyQ) diseases as
exemplified by Huntington’s disease (HD) and related
ataxias afflict millions worldwide and remains a signifi-
cant and unresolved burden facing ageing populations.
Many genetic factors including specific causative muta-
tions have been identified but therapies for these debili-
tating and eventually fatal disorders are lacking. These
disorders are associated with the unifying theme of
accumulation of toxic, misfolded protein aggregates or
inclusion bodies followed by progressive neuronal dys-
function, eventual neuronal loss and death. In many
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to protein aggregation have been indentified and there
is growing evidence that the cellular protein quality con-
trol systems are an underlying common denominator of
these diseases [1]. In different individuals, the suscept-
ibility to disease-related mutations and the time of onset
of age-related neurodegeneration differ significantly sug-
gesting the importance of additional genetic factors or
genetic variation [2]. Despite this, relatively few genetic
factors shared between neurodegenerative diseases have
been identified so far.
Knowledge of genetic regulators of neurodegeneration
is important not only for an understanding of potential
neuroprotective mechanisms but for the identification of
potential new drug targets. The use of small model
organisms with short generation times such as C. ele-
gans, S. cerevisiae and D. melanogaster, has facilitated
testing of hypotheses to illuminate a prospective cellular
cause of protein-misfolding diseases like HD, PD,
Amyotrophic Lateral Sclerosis (ALS) and AD or neuro-
protective mechanisms against neurodegeneration [3,4].
Disease models in these organisms have also allowed
screening of potential genetic modifiers of the late-onset
cellular and behavioural phenotypes. Screening can be
performed by molecular, genetic and chemical manipu-
lations of gene function, i.e. using mutagenesis (deletion
libraries, transposon based insertion), transgenic overex-
pression of exogenous human misfolding disease-related
proteins, or RNA interference (RNAi)-mediated knock-
down to determine the loss- or gain-of-function pheno-
types. Previous studies have ranged from the
examination of the effects of genetic manipulation of
small number of targeted genes to whole genome
screens. In addition, a wide range of disease models has
been examined. For example in C. elegans,t h em o s t
widely studied model organism in this context, multiple
tissue-specific transgenic models manifesting pathologi-
cal phenotypes that faithfully recapitulate many cellular
and molecular pathologies of complex neurodegenera-
tive disease processes have been used [5,6]. These mod-
els have been based on muscular or neuronal expression
of aggregation-prone proteins such as mutant tau,
superoxide dismutase (SOD1), a-synuclein, polyQ con-
structs, Huntingtin fragment and toxic amyloid beta 1-
42 (Ab1-42) [7], and has allowed identification of modi-
fiers and cellular processes of a-synuclein inclusion for-
mation [8,9], polyQ [10] and mutant SOD1 aggregation
[11], a-synuclein and polyQ-induced toxicity [12,13]
and tau-induced pathology [14]. The model organism
approach and the various disease models that have been
studied have been extensively reviewed in recent years
and will not be described further here [5,6,15-20].
It might be expected that common features should
underlie the different pathways that lead to or protect
from the phenotypes in diverse neurodegenerative dis-
eases. One key question of interest, therefore, is the
extent to which the model organism studies have identi-
fied common genetic regulators of neurodegenerative
disease. While chaperone proteins involved in protein
folding have emerged as common factors [1] it has
appeared that relatively few overlapping genetic regula-
tors have been identified from genetic screens using dif-
ferent models. For example the same group using a
whole genome RNAi screen in C. elegans models of both
polyQ and a-synuclein aggregation reported only a single
gene overlap from a large number of hits identified
[9,10]. Use of RNAi screens in Drosophila cell lines with
similar huntingtin polyQ models identified 21 [21] and
126 [22] regulators respectively. Only three of these iden-
tified regulators overlapped between the two studies. In
addition, only two regulators from the Drosophila cell
line studies overlapped with those found in an assay for
polyQ aggregation in human cells [23] and had opposite
effects. In another study, regulation of toxicity due to
expression of either a-synuclein or a huntingtin fragment
in yeast was found to involve non-overlapping sets of
genes [24]. One problem in comparing across all screens
is the different disease models that have, for example,
used toxicity in all or only in specific neurons or alterna-
tively protein aggregate formation in either neurons or
muscle as the disease phenotype [5,6,17]. An initial analy-
sis of different screens based on the biological function of
identified genes did indicate the role of common and dif-
fering functional classes of modifier genes involved in
various cellular process including regulation of protein
homeostasis, vesicular traffic and transcriptional control
[17]. A significant problem in understanding the com-
monality of genetic regulators is the need for careful
matching of protein orthologues across the three model
species and this has not been carried out systematically.
We have set out to use data from published genetic
screens in C. elegans, S. cerevisiae and D. melanogaster
to generate an integrated data set of genetic regulators
of neurodegeneration. In order to do this we have used
C. elegans as the reference point since this organism is
most applicable for large scale screens and has been
very widely used for study of neurodegenerative
mechanisms. For C. elegans and D. melanogaster we
have focussed on screens at the whole organism level as
these have the additional possibility of identifying non-
cell autonomous factors. Thea i mo ft h i ss t u d yw a st o
give an improved indication of shared genetic factors
and to provide a resource for future studies on neurode-
generation and neuroprotection.
Results and Discussion
A series of papers were collated in which genetic
approaches were used to identify regulators of
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whole organism models in C. elegans and D. melanoga-
ster (Figure 1). As well as medium and large scale
screens we also included examples of targeted small
scale genetic studies of candidate genes to allow inclu-
sion of other regulators. There are additional candidate
gene studies or screens on cells lines from Drosophila
for example [21,22,25] that have not been included.
Data from the published literature was first used to
compile a list of genes identified as regulators in various
neurodegeneration models in C. elegans (Additional file
1). For studies in D. melanogaster and S. cerevisiae,l i s t s
of the gene regulators was compiled and then the exis-
tence and identity of any C. elegans orthologues was
examined for each genetic regulator using the Princeton
Protein Orthology Database [26]. Confirmation of the
existence of single or multiple potential orthologues
generated lists of the C. elegans orthologues of genetic
regulators of neurodegeneration from studies in D. mel-
anogaster (Additional file 2) and S. cerevisiae (Additional
file 3). From this analysis of a total of 950 identified
genetic modifiers of neurodegeneration, 675 were found
to have orthologues that could be identified in the C.
elegans genome (Table 1). The genes that did not have
identifiable orthologues in C. elegans are likely to be
yeast- or fly-specific or simply not represented in the C.
elegans genome.
From the combined lists, a total of 624 distinct genes
encoding genetic regulators were identified (Additional
file 4). An initial analysis of the genetic modifiers based
on cellular function was carried out. As described pre-
v i o u s l yf r o mt h i st y p eo fa n a l y s i s[ 1 7 ]i tc o u l db es e e n
that the genes covered a wide range of cellular functions
covering 17 different classes of biological function (Fig-
ure 2). There was, however, a concentration of genes in
certain functional classes. Genes involved in protein
folding (e.g. heat shock proteins), protein degradation
and autophagy were discovered across multiple disease
models. Genes involved in transcriptional regulation
were identified across all the polyQ and tau-disease
models. It was noteworthy that the a-synuclein disease
models produced a particular concentration of regula-
tors functional in vesicular transport (e.g. rab-1)
although these did appear, albeit less frequently, in stu-
dies on other disease models.
Of more interest was the potential identification of spe-
cific genes with overlapping modifying roles in different
disease models and model organisms. Within the set of
distinct C. elegans orthologues we found 34 that had
been indentified in more than one study. These are
shown in Table 2 and in an expanded version with addi-
tional information in Additional file 5. Significantly, all
of these genes have human orthologues (Additional file
5). The overlapping regulators fell into several different
functional classes (Table 3) based on their classification
in the original studies.
A recent study has extended the identification of sup-
pressors of polyQ aggregation in C. elegans [10] by
examining whether knock down of their human ortholo-
gues would suppress aggregation of mutant huntingtin
in a human cell line. Of the 177 human orthologues, 26
inhibited aggregation in the HK293 cells supporting the
idea that genetic regulators identified in C. elegans
would have a conserved function relevant for a human
model [23]. Three of the human suppressors correspond
to the overlapping regulators in Table 2 (hsp-1, cct-4
and cct-5) and a fourth was an additional subunit of
TCP-1 (cct-2).
Many but not all of the overlapping genes in Table 2
are known to be expressed in adult neurons in C. ele-
gans where they could, therefore, have a physiological
Figure 1 Steps in the integrated analysis of genetic regulators
identified from genetic approaches in model organisms.
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important consideration as some of the worm disease
models are based on aggregate formation in muscle
rather than neuronal cells. It should be noted that the
data available in WormBase on the cellular expression
of worm proteins is variable and so the question of neu-
ronal expression is uncertain for some of the regulators.
Two genes, bli-3 and phi-49 have, however, non-neuro-
nal and restricted cell type expression. This may suggest
that they may be unlikely to be physiological regulators
of neurodegeneration in the worm but alternatively they
could, for example, affect release of extracellular factors
that act on neurons.
The overlapping gene set included regulators identi-
fied in more than one study but only using the same or
similar type of disease model in a single species (Table
2). Others, however, had been identified in multiple
models and/or species. Amongst the latter were, unsur-
prisingly, members of families with functions related to
protein folding such as hsp-1, hsf-1, dnj-13, cct-4,a n d
Table 1 Genetic studies for the identification of regulators of neurodegeneration models in C.elegans, S. cerevisiae and
D. melanogaster
Study
Number
Primary model
Organism
Disease
model
Expressed construct Screen Number of
Genetic modifiers
Orthologues in
C. elegans
Reference
1 C. elegans P Htt-Q0, Q24, Q33,
Q35, and Q40
Genome-wide RNAi 186 186 [10]
2 C. elegans SOD G85R SOD Genome-wide RNAi 81 81 [11]
3 C. elegans SW T a-synuclein Genome-wide RNAi 82 82 [9]
4 C. elegans T Tau P301L and
V337M
Genome-wide RNAi 75 75 [14]
5 C. elegans SW T a-synuclein Hypothesis-driven RNAi 20 20 [65]
6 C. elegans P Htt-Q150 Candidate genes 12 12 [37]
7 C. elegans SW T a-synuclein Systematic RNAi screen 11 11 [68]
8 C. elegans P Htt-Q128 Candidate genes 4 4 [13]
9 C. elegans Ab Ab1-42 Candidate genes 2 2 [69]
10 C. elegans T Tau P301L and
V337M
Forward genetic 2 2 [70]
11 C. elegans T Tau V337M Candidate genes 2 2 [71]
12 C. elegans P Htt-Q32, Q40, Q56,
Q79
Candidate genes 2 2 [72]
13 C. elegans P Htt-Q2 and Q150 Candidate genes 1 1 [12]
14 S. cerevisiae P and S Htt-Q20, Htt-Q53,
A53T a-synuclein
Genome-wide genetic 138 41 [24]
15 S. cerevisiae S a-synuclein Selected genetic screen 77 20 [73]
16 S. cerevisiae Ab Ab1-42 Genome-wide genetic 40 11 [60]
17 S. cerevisiae P Htt-Q103 Genome-wide loss-of-
function suppressor
30 5 [50]
18 S. cerevisiae SW T a-synuclein Genome-wide overexpression 22 7 [58]
19 S. cerevisiae SW T a-synuclein Candidate genes 5 1 [59]
20 D. melanogaster T Tau V337M Large-scale genetic 30 14 [74]
21 D. melanogaster P Htt-Q128 protein interaction and
selected genetic screen
32 34 [75]
22 D. melanogaster P SCA182Q and Htt-
Q128
Selective genetic modifier
screen
24 20 [34]
23 D. melanogaster T Tau V337M Large-scale genetic 24 10 [76]
24 D. melanogaster P Htt-Q127 Selective genetic modifier
screen
10 2 [77]
25 D. melanogaster P SCA3trQ78 Genome-wide screen 18 17 [63]
26 D. melanogaster P SCA1 30Q and 82Q Large-scale genetic 17 11 [78]
27 D. melanogaster P Htt-Q127 Genome-wide screen 2 1 [79]
28 D. melanogaster S A30P and A53T a-
synuclein
Candidate gene 1 1 [80]
Total 950 675
The number of regulators of neurodegeneration that were identified in each study is shown along with the number of these genes with orthologues in C
elegans. The disease models include organisms expressing forms of b-amyloid (AB), polyQ expansions (P), wild type or mutant a-synuclein (S), mutant superoxide
dismutase (SOD), or mutant tau (T).
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tion, three genes encoding enzymes involved in ubiquiti-
nation, chn-1, ubc-8, and let-70 were identified in more
than one study. The mammalian orthologues, CHIP and
Ube2D2 respectively, of chn-1 (an E3 ligase) and let-70
(E2 conjugating enzyme) are known to interact directly
[28,29] as are CHIP and p97 (cdc-48.1) [30]. Interest-
ingly, CHIP also provides a further link between ubiqui-
tination and protein folding pathways based on its
known interactions with and ability to ubiquitinate
Hsc70 and HSF1 (Figure 3). These data would put
CHIP at a key point in two pathways that modify neuro-
degeneration. The idea that CHIP is a key player in the
regulation of neurodegeneration is reinforced by the evi-
dence that it has been shown to ubiquitinate a-synu-
clein [31] and ataxin-1 [32] and to stimulate the
ubiquitin ligase activity of the PD gene product Parkin
[33]. In addition, CHIP has a neuroprotective role in the
neurotoxicity caused by over-expression of ataxin-1 in a
fly model [32]. Taken together with the screens included
here [14,34] in which CHIP orthologues were found to
modify neurodegeneration models including those based
on tau-induced pathology, polyQ-related disorders and
a-synuclein over-expression, it appears that CHIP could
play a key protective role in multiple neurodegenerative
diseases.
Another significant functional grouping in the shared
modifiers is the three histone deacetylases, sir-2.1, hda-1
and sin-3 which were identified in both polyQ and a-
synuclein disease models in flies and worms. The mam-
malian orthologues of hda-1 (human HDAC1) and sin3
(human SIN3B) interact directly and function as part of
a protein complex to repress gene transcription [35,36].
A selective study on histone deacetylases in C. elegans
Figure 2 Functional profiling of genetic modifiers identified in diverse screens. Comparative analysis of modifiers identified in worm (Ce)
models of polyQ, tau, SOD and a-synuclein aggregation, yeast (Sc) models of misfolded a-synuclein and Htt toxicity and fly (Dm) models of
misfolded tau and polyQ toxicity from diverse screens reveals that the identified modifier genes function in a wide variety of biological
processes as defined in the original studies. The blue filled box indicates that one or more genes in this category were identified. The number of
the study indicated refers to the numbering in Table 1.
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loss of either hda-1 or sir-2.1 exacerbated neurodegen-
eration due to polyQ toxicity [37]. Overexpression of
sir-2.1 had been suggested to increase longevity in C.
elegans [38] leading to widespread study of the potential
anti-aging effects of the related sirtuins in many species
including a possible role in the effects of calorie-restric-
tion on life span in C. elegans [39] and other species
[40]. It might be thought that its neuroprotective effect
could be related to its general effect on ageing. Recent
work has, however, largely eliminated a role for sir-2.1
in increasing lifespan following the removal of an addi-
tional unrelated mutation in the worm strain studied. In
contrast, a neuroprotective effect on a polyQ model of
neurodegeneration remained associated with sir-2.1
overexpression [41]. A neuroprotective role of calorie
Table 2 Overlapping genetic regulators of neurodegeneration with orthologues in C.elegans
Sequence
Name
Gene name Description Organism Disease
model
Expression in
neurons
Y53C10A.12 hsf-1 Heat-shock transcription factor worm Ab, P, S, SOD,
T
yes
F26D10.3 hsp-1 HSP70 protein family fly, worm P, T, S yes
F54D5.8 dnj-13 Molecular chaperone (DnaJ) fly P, T ?
K01C8.10 cct-4 Chaperone containing TCP-1 worm P, SOD yes
C07G2.3 cct-5 Chaperone containing TCP-1 worm P, SOD ?
T09B4.10 chn-1 C-term of HSP-70 interacting protein (E3 ubiquitin
ligase)
fly, worm P, T yes
Y94H6A.6 ubc-8 Ubiquitin conjugating enzyme fly, yeast P, S ?
M7.1 let-70 E2 Ubiquitin conjugating enzyme fly P yes
C06A1.1 cdc-48.1 AAA ATPase, functions as a ubiquitin-related chaperone worm P Yes
F52D10.3,
M117.2
ftt-2, par-5 14-3-3 family fly P yes
C39F7.4 rab-1 Small Ras-like GTPase Rab1 fly, yeast,
worm
P, S yes
B0361.10 ykt-6 SNARE protein YKT6 yeast S ?
C54H2.5 sft-4 SURF-4 related to cargo transport protein ERV29 worm, yeast S yes
Y54E2A.12 tbc-20 Predicted GTPase activator protein yeast S ?
R11A8.4 sir-2.1 NAD-dependent histone deacetylase fly, worm P, S Yes
C53A5.3 hda-1 Histone deacetylase 1 fly, worm P, S No?
F02E9.4 sin-3 SIN3 family of histone deacetylase subunits fly P, S yes
F59F4.1 - Acyl-CoA oxidase fly, yeast,
worm
P, S, T ?
ZK256.1a pmr-1 Golgi P-type ATPase Ca2+ -pump yeast S yes
W08D2.5, catp-6 Predicted lysosomal P-type ATPase worm, yeast S ?
Y43F4B.4 npp-18 Nuclear pore complex protein fly P yes
F49E10.5 ctbp-1 Transcriptional co-repressor homolog fly P ?
K08F8.6 let-19 Transcriptional cofactor fly P yes
T17E9.1 kin-18 Serine-threonine protein kinase fly, worm P, T yes
H18N23.2 - Protein phosphatase, regulatory subunit PPP1R3C/D fly, worm P, SOD ?
T14F9.1 vha-15 (phi-
52)
Vacuolar ATPase subunit H worm P, S Yes
T21E12.4 dhc-1 Dynein heavy chain fly, worm P Yes
Y113G7B.18 mdt-17 MeDiaTor worm S, SOD ?
Y116A8C.35 uaf-2 U2AF splicing factor worm P, S Yes
F56C11.1 bli-3 Homologue of dual oxidase worm P, SOD No
C32E8.10c unc-11 Clathrin-adaptor protein AP180 worm, yeast Ab, P Yes
JC8.10b unc-26 Synaptojanin worm, yeast Ab, P Yes
ZK742.1a xpo-1 Exportin-1 Fly, yeast Ab,P ?
C05C8.7 phi-49 Mannose-6-phosphate isomerase worm P, SOD No
The genes were included if they were identified in more than one genetic screen. The disease models included organisms expressing forms of b-amyloid (AB),
polyQ expansions (P), wild type or mutant a-synuclein (S), mutant superoxide dismutase (SOD), or mutant tau (T). Under expression in neurons a question mark
indicates that no data are available in Wormbase.
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mediated by sir-2.1 [42]. SIRT1, the mammalian ortho-
logues of sir-2.1 and other histone deacetylases have
been well established to regulate neurodegeneration and
have been suggested as potential drug targets [43,44].
The use of histone deacetylases inhibitors is currently
being examined for treatment of neurodegenerative
diseases but there are concerns about the potential det-
rimental effects of these inhibitors [43,45].
The epsilon isoform of the 14-3-3 proteins (CG31196)
was identified in screens in the fly as a regulator of
polyQ-mediated neurotoxicity. This fly protein has two
worm orthologues (ftt-2 and par-5). One of these, ftt-2
has also been shown to be neuroprotective when over-
expressed in a worm model of a-synuclein-mediated
neurotoxicity [46]. It has been shown that 14-3-3 pro-
teins may increase lifespan and can interact with sir-2.1
[47,48]. Recent work [49] has suggested that the neuro-
protective role of 14-3-3 proteins in mammalian cells
may be due to inhibition of the apoptotic factor Bax [49].
A screen of genetic regulators of toxicity due to a
mutant huntingtin fragment in S. cerevisiae identified
Bna4 (kynurenine 3-monooxygenase) as the most potent
suppressor [50]. Orthologues of Bna4 exist in D. mela-
nogaster (CG1555) and in C. elegans (R07B7.5) but they
were not identified in any of the screens in these organ-
isms in Table 1. Nevertheless, recent studies have identi-
fied neuroprotective effects of inhibition or loss of
kynurenine 3-monooxygenase and the kynurenine path-
way in general in a Huntington’sd i s e a s em o d e li nD.
melanogaster and both Huntington’sa n dA l z h e i m e r ’s
d i s e a s em o d e l si nm i c e[ 5 1 , 5 2 ]s u g g e s t i n gas i m i l a rr o l e
in different organisms. Significantly, the study in D. mel-
anogaster [52] also showed that loss of function in the
tryptophan 2,3-dioxygenase gene (vermillion) the first
enzyme in the kynurenine pathway was neuroprotective.
The C. elegans orthologue of tryptophan 2,3-dioxygen-
ase (C28H8.11) was one of the suppressors of a-synu-
clein inclusion formation identified in a genome wide
screen in C. elegans [9]. These two enzymes can be
regarded, therefore, as general regulators of neurodegen-
eration across species and diseases.
Recent work has implicated defects in autophagy as a
contributor to neurodegeneration and the process of
autophagy as a key protective mechanism in preventing
neurodegeneration [53-56]. Within the list of regulatory
genes identified none encoded direct components of the
autophagy machinery. Interestingly, however, the list of
overlapping genes included sir-2.1 orthologues of which
are involved in signalling pathways that control autop-
hagy and thereby lifespan [53,57]. In addition, rab-1 was
discovered in genetic screens as a regulator of a-synu-
clein-mediated protein aggregation in a yeast model and
is also effective in neuroprotection in worms and flies
[58,59]. The orthologues of rab-1 (specifically Rab1a in
mammals) were recently shown to rescue an autophagy
defect due to a-synuclein overexpression in mammalian
cells and in Drosophila implicating the Rab1a isoform in
autophagosome formation [54].
A genome-wide screen for genes that modify toxicity
of Ab1-42 in S. cerevisiae has identified 23 suppressor
Table 3 Biological processes associated with the
identified overlapping genetic regulators of
neurodegeneration.
Biological process Genes
Heat shock transcription factor hsf-1
Molecular chaperones hsp-1, dnj-13, cct-4, cct-5
Ubiquitin related chn-1, ubc-8, let-70, cdc-48.1
Histone deacetylases sir2.1, had-1, sin-3
Signalling/chaperone fft-2/par-5
Transcriptional cofactor/regulator ctbp-1, let-19, mdt-17, uaf-2
Nucleopore/nuclear export npp-18, xpo-1
Vesicular transport rab-1, sft-4, tbc-20, ykt-6, dhc-1
Endocytosis unc-11, unc-26
Transport ATPase catp-6, pmr-1, vha-15
Protein phosphorylation kin-18, H18N13.2
Other cellular processes bli-3, phi-49, F59F4.1
Figure 3 The diagram shows known binary protein-protein
interactions between the molecular chaperone and ubiquitin-
related overlapping regulators in Table 2. The interactions are
included if they were identified between orthologues of the
proteins from any species and are shown labelled with the names
of the human orthologues with those involved in protein folding
(chaperones) in blue and those in ubiquitin-related pathways in red.
The human orthologues and their corresponding C. elegans
orthologues are as follows: HSF1, hsf-1; Hsc70, hsp-1; DnaJB5, dnj-13;
CHIP, chn-1; p97, cdc-48.1; Ube2D2, let-70.
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and 11 C. elegans orthologues. Three of the conserved
yeast suppressors (YAP1802, INP52 and SLA1)h a v e
known functions in endocytosis. In addition, the human
orthologues (PICALM, SYNJ1 and SH3KBP1) have been
found from genome-wide association studies to be risk
f a c t o r st h e m s e l v e s( PICALM) or alternatively (SYNJ1
and SH3KBP1) to interact with known risk factors for
Alzheimer’s disease [61,62]. Examination of the effect
the C. elegans orthologues (unc-11, unc-26 and
Y44E3A.4)i naw o r mA b1-42 model confirmed that the
endocytic genes had protective roles in this species [60].
Interestingly, a protective role for unc-11 and unc-26
has previously been identified in a C. elegans huntingtin
polyQ disease model [13]. Overall these studies suggest
an important role for clathrin-mediated endocytosis in
regulation of toxicity in different disease models.
The other overlapping modifiers in Table 2 do not fit
obviously into related functional classes but some of
these genes may be generally significant. One that is
noteworthy is the Acyl-CoA oxidase that was identified
in all three model species in different disease models.
The single orthologue in yeast, pox1, was identified as a
regulator of a-synuclein toxicity in yeast [24]. The fly
orthologue FBgn0027572 (CG5009) was identified in a
genome wide screen for regulators of polyQ ataxin-3-
mediated neurodegeneration in the eye where its over-
expression suppressed the phenotype [63]. In addition,
CG5009 also suppressed tau-mediated toxicity. Search
of the Princeton Protein Orthology Database identifies
seven orthologues of the yeast and fly genes in C. ele-
gans (C48B4.1, F08A8.2, F08A8.3, F08A8.4, F08A8.1,
F59F4.1, F25C8.1) and an additional orthologue has
been postulated (F58F9.7) [64]. It is possible that all of
the predicted worm acyl CoA oxidases could have over-
lapping functions. Of these orthologues, however, only
the worm F59F4.1 gene was identified as a regulator of
a-synuclein aggregate formation in a large scale RNAi
screen where its knock down enhanced aggregation [65]
suggesting that this particular orthologue has a non-
redundant role. Interestingly in the fly model CG5009
was functionally linked to protein folding mechanisms
based on an examination of effects of its over-expression
on defects due to expression of a dominant negative
form of Hsp70 [63]. The effect of over-expression of
CG5009 was to enhance the defect, an effect that was
also seen with the Hsp70 co-chaperone DnaJ-1. A single
orthologue (ACOX1) is present in mammals where it is
localised to peroxisomes and functions in b-oxidation of
fatty acids. The potential importance of peroxisomes in
general and more specifically acyl-CoA oxidase in neu-
roprotection is highlighted by the Zellweger class of per-
oxisomal biogenesis disorders in which there are severe
neurological abnormalities. Mutations in ACOX1
(OMIM number 609751) are liked to clinical conditions
which include a range of neurological problems. The
function of acyl-CoA oxidase in fatty acid metabolism
and its widespread tissue distribution results, however,
in a range of clinical symptoms in conditions of reduced
enzyme activity [66]. Acyl CoA oxidase has not pre-
viously been given serious consideration as regulator of
neurodegeneration in specifically-targeted studies.
Conclusions
An integrated analysis of data available from genetic
screens of regulators of neurodegeneration in various
disease models in yeast, fly and worms has identified 34
shared regulators. This is a higher number than was
expected from previous studies. There are some addi-
tional candidate gene studies and screens on cell lines
that were not included in this analysis and so the num-
ber could potentially be increased by incorporation of
these. Several of the shared regulators identified here
are members of classes of genes encoding proteins
involved in protein folding and/or ubiquitin-dependent
pathways. These form a group of 6 directly interacting
proteins with the E3 ligase CHIP linking the two func-
tional pathways. Other shared regulators that have
received previous attention in targeted studies on neuro-
protection included histone deacetylases and 14-3-3 pro-
teins. Interestingly, other shared regulators emerged
which have not previously been considered as key regu-
lators of neurodegeneration including acyl-CoA oxidase.
The role in neuroprotection of acyl-CoA oxidase, in par-
ticular, clearly warrants further study.
Methods
Literature Mining
Studies using genetic approaches to study genetic regu-
lators of neurodegenerative disease models in C. elegans,
S. cerevisiae and D. melanogaster were identified using
key word searches in PubMed http://www.ncbi.nlm.nih.
gov/sites/entrez). The identified published literature was
manually curated to compile a collection of experimen-
tally delineated genetic modifiers of protein aggregation,
misfolding and neurodegeneration in C. elegans, S. cere-
visiae and D. melanogaster. Files containing full lists of
modifiers in the online supplemental materials of the
papers were converted and imported into Microsoft
Excel.
Orthologue search
Individual worm orthologues of yeast and fly modifier
genes were identified by searching the Princeton Protein
Orthology Database (P-POD version 4) (http://ortholog.
princeton.edu/findorthofamily.html) [26] and use of
OrthoMCL [67] to determine the appropriate ortholo-
gues. These identifications were further checked and
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Page 8 of 11refined by consulting WormBase (http://www.wormbase.
org/) using the “best Blast score”, Saccharomyces Gen-
ome Database (SGD) (http://www.yeastgenome.org) and
FlyBase (http://flybase.org) and use of BLAST searches
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Information on
the list of modifiers was further refined by conducting
search queries in the bioinformatic interfaces at Worm-
Base [WormBase Web site, available at http://www.
wormbase.org, release version WS224, April, 2011], Bio-
mart [http://www.biomart.org/], and GExplore 1.1
[http://genome.sfu.ca/gexplore/].
Analysis of protein-protein interactions
Known protein-protein interactions amongst ortholo-
gues of the overlapping genetic regulators was identified
by manual searches using the protein interaction data-
bases BioGrid, IntAct, MINT, the Human Protein Refer-
ence Database and by literature searches on PubMed
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